Minimally invasive treatment of benign prostatic hyperplasia with high-intensity focused ultrasound using the Sonablate system: an updated report of Phase III clinical studies conducted in the US

Thomas A. Gardner; Michael O. Koch; Arieh Shalhav; Richard Bihrle M.D.; Richard S. Foster M.D.; Christopher Steidle; Ivan Grunberger; Alan Seftel; Martin Resnick; James Cochran; Victor Rao; Narendra T. Sanghvi

doi:10.1117/12.432046

17 June 2002 Minimally invasive treatment of benign prostatic hyperplasia with high-intensity focused ultrasound using the Sonablate system: an updated report of Phase III clinical studies conducted in the USA

Thomas A. Gardner, Michael O. Koch, Arieh Shalhav, Richard Bihrle M.D., Richard S. Foster M.D., Christopher Steidle, Ivan Grunberger, Alan Seftel, Martin Resnick, James Cochran, Victor Rao, Narendra T. Sanghvi

Author Affiliations +

Proceedings Volume 4609, Lasers in Surgery: Advanced Characterization, Therapeutics, and Systems XII; (2002) https://doi.org/10.1117/12.432046
Event: International Symposium on Biomedical Optics, 2002, San Jose, CA, United States

Abstract

Phase III multicenter study was conducted in the USA under the FDA approved protocol, to establish the safety and efficacy of High Intensity Focused Ultrasound (HIFU) in the treatment of Benign Prostatic Hyperplasia (BPH) using the Sonablate? system. A total of sixty eight patients have been treated to date in the Phase III study. Transrectal probes capable of real-time ultrasound imaging of the prostate and well as delivering the HIFU energy to the selected region in the prostate gland were used. Probes with different focal lengths were used to treat different size of prostate glands. The patients were treated in one treatment session and were followed up to a period of one year following the treatment. The subjects underwent physical exam, Digital Rectal Examination (DRE), cystoscopy, Transrectal Ultrasound (TRUS), blood work, urine exam and were given standard questionnaires before treatment and during the follow up period. Under this protocol HIFU was found to be safe and effective in reducing the BPH related symptoms and improving the peak urinary flow rate with preservation of sexual function and no permanent side effects.

Citation Download Citation

Thomas A. Gardner, Michael O. Koch, Arieh Shalhav, Richard Bihrle M.D., Richard S. Foster M.D., Christopher Steidle, Ivan Grunberger, Alan Seftel, Martin Resnick, James Cochran, Victor Rao, and Narendra T. Sanghvi "Minimally invasive treatment of benign prostatic hyperplasia with high-intensity focused ultrasound using the Sonablate system: an updated report of Phase III clinical studies conducted in the USA", Proc. SPIE 4609, Lasers in Surgery: Advanced Characterization, Therapeutics, and Systems XII, (17 June 2002); https://doi.org/10.1117/12.432046

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available